GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q4 FY25 results · Jan–Mar 2025
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹974.37 crore (up 4.8% from Q4 FY24) and net profit of ₹262.87 crore (up 35.2% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 974.37 | 929.80 | +4.8% | 949.42 | +2.6% |
| Other income | 40.68 | 29.83 | +36.4% | 35.07 | +16.0% |
| Total income | 1,015.05 | 959.63 | +5.8% | 984.49 | +3.1% |
| Profit before tax | 358.57 | 270.62 | +32.5% | 308.10 | +16.4% |
| Net profit for the period | 262.87 | 194.48 | +35.2% | 229.88 | +14.4% |
| EPS, basic (₹) | 15.52 | 11.48 | +35.2% | 13.57 | +14.4% |
| Net margin (%) | 27.0 | 20.9 | 24.2 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 966.08 | 910.87 | +6.1% | 946.36 | +2.1% |
| Other income | 39.46 | 29.87 | +32.1% | 35.06 | +12.5% |
| Total income | 1,005.54 | 940.74 | +6.9% | 981.42 | +2.5% |
| Profit before tax | 354.90 | 268.71 | +32.1% | 306.35 | +15.8% |
| Net profit for the period | 260.14 | 193.08 | +34.7% | 228.58 | +13.8% |
| EPS, basic (₹) | 15.35 | 11.39 | +34.8% | 13.49 | +13.8% |
| Net margin (%) | 26.9 | 21.2 | 24.2 |
Consolidated
- Filed with BSE
- 13 May 2025, 23:53 IST
- Board meeting
- 13 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 May 2025, 23:53 IST
- Board meeting
- 13 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE